Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review

Objective To investigate the efficacy of venlafaxine for neuropathic pain and review literature to determine if the medication provides adequate neuropathic pain relief. Methods Literature was reviewed on MEDLINE using various key words. These key words include: "venlafaxine and pain," "venlafaxine ER and pain," "venlafaxine XR and pain," "venlafaxine and neuropathic pain," "venlafaxine and neuropathy," "SSRI and neuropathic pain," "SSRI and neuropathy," "SNRI and neuropathic pain," "SNRI and neuropathy," "serotonin reuptake inhibitor and neuropathic pain," "serotonin reuptake inhibitor and neuropathy," "serotonin norepinephrine reuptake inhibitor and neuropathic pain" and "serotonin norepinephrine reuptake inhibitor and neuropathy." Using this guideline, 13 articles were reviewed. Results A total of 13 studies reviewed, which are organized by date and diagnosis. It is evident that in the majority of studies, when compared with a placebo, there was a clinical significant reduction in neuropathic pain relief when using venlafaxine. Additionally, one study showed even more significant pain relief when using higher doses of venlafaxine (at least 150 mg). However, when compared with alternative neuropathic medications, venlafaxine for the most part did not perform any better in terms of efficacy. Conclusion In conclusion, venlafaxine is a safe and well-tolerated analgesic drug for the symptomatic treatment of neuropathic pain, and there is limited evidence that high-dose venlafaxine (150 mg/day) can be even more beneficial. While the present evidence is quite encouraging regarding venlafaxine's use for neuropathic pain, further research is needed to continue to expand on these findings, particularly when in consideration with other possible pharmacological agents.

[1]  V. Coelho,et al.  Pathophysiology of the Constant Burning, Tingling Element of Neuropathic Pain: a New Hypothesis , 2014, Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery.

[2]  R. Treede,et al.  Neuropathic low back pain in clinical practice , 2016, European journal of pain.

[3]  G. Alpak,et al.  Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case–control study , 2016, Supportive Care in Cancer.

[4]  M. Henman,et al.  Venlafaxine for neuropathic pain in adults. , 2015, The Cochrane database of systematic reviews.

[5]  A. Heinemann,et al.  Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial. , 2015, Archives of physical medicine and rehabilitation.

[6]  D. Afshari,et al.  Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy , 2014, Neurosciences.

[7]  S. Rajbhandari,et al.  Pathogenesis of Painful Diabetic Neuropathy , 2014, Pain research and treatment.

[8]  R. Sansone,et al.  STRESS AND TRAUMA: Psychotherapy and Pharmacotherapy for Depersonalization/Derealization Disorder. , 2014 .

[9]  Steven P. Cohen,et al.  Neuropathic pain: mechanisms and their clinical implications , 2014, BMJ : British Medical Journal.

[10]  R. Sansone,et al.  Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. , 2014, Innovations in clinical neuroscience.

[11]  M. Swan,et al.  Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. , 2013, Pain medicine.

[12]  E. Raymond,et al.  Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  C. Voscopoulos,et al.  When does acute pain become chronic? , 2010, British journal of anaesthesia.

[14]  T. Yaguchi,et al.  Noradrenaline stimulates ATP release from DRG neurons by targeting β3 adrenoceptors as a factor of neuropathic pain , 2010, Journal of cellular physiology.

[15]  Tammy J. Lindsay,et al.  Treating diabetic peripheral neuropathic pain. , 2010, American family physician.

[16]  Y. Amr,et al.  Evaluation of Efficacy of the Perioperative Administration of Venlafaxine or Gabapentin on Acute and Chronic Postmastectomy Pain , 2010, The Clinical journal of pain.

[17]  William Eardley,et al.  An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy , 2010, Journal of pain research.

[18]  R. Treede,et al.  Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update SUPPLEMENT ARTICLE , 2010 .

[19]  W. Faber,et al.  Pain, Pain, Go Away , 2009 .

[20]  P. Christo,et al.  Pharmacological and interventional treatments for neuropathic pain , 2009 .

[21]  S. Waxman,et al.  Multiple sodium channel isoforms and mitogen‐activated protein kinases are present in painful human neuromas , 2008, Annals of neurology.

[22]  R. Sansone,et al.  Pain, pain, go away: antidepressants and pain management. , 2008, Psychiatry (Edgmont (Pa. : Township)).

[23]  S. Montgomery Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants , 2008, CNS Spectrums.

[24]  H. Kayabaşı,et al.  The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. , 2008, Journal of diabetes and its complications.

[25]  Xiao Ying-guang Venlafaxine Extended Release and Sertraline in the Treatment of Depression-control Study , 2007 .

[26]  G. Wilkinson,et al.  Seminars in general adult psychiatry , 2007 .

[27]  Qifu Li,et al.  Effects of Venlafaxine and Carbamazepine for Painful Peripheral Diabetic Neuropathy: A Randomized, Double-blind and Double- dummy, Controlled Multi-center Trial , 2006 .

[28]  Ralf Baron,et al.  Mechanisms of Disease: neuropathic pain—a clinical perspective , 2006, Nature Clinical Practice Neurology.

[29]  L. Arendt-Nielsen,et al.  The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study , 2005, European journal of pain.

[30]  Olivier Poirot,et al.  Silencing of the Cav3.2 T‐type calcium channel gene in sensory neurons demonstrates its major role in nociception , 2005, The EMBO journal.

[31]  E. Kalso,et al.  Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. , 2004, Journal of orofacial pain.

[32]  T. Jensen,et al.  Venlafaxine versus imipramine in painful polyneuropathy , 2003, Neurology.

[33]  E. Kalso,et al.  Venlafaxine in neuropathic pain following treatment of breast cancer , 2002, European journal of pain.

[34]  Sulayman D. Dib-Hajj,et al.  Nav1.3 Sodium Channels: Rapid Repriming and Slow Closed-State Inactivation Display Quantitative Differences after Expression in a Mammalian Cell Line and in Spinal Sensory Neurons , 2001, The Journal of Neuroscience.

[35]  D. Moulin,et al.  Treatment of Neuropathic Pain with Venlafaxine , 2001, The Annals of pharmacotherapy.

[36]  R. Baron Peripheral Neuropathic Pain: From Mechanisms to Symptoms , 2000, The Clinical journal of pain.

[37]  S. Preskorn,et al.  Evidence of the dual mechanisms of action of venlafaxine. , 2000, Archives of general psychiatry.

[38]  D. Bouhassira,et al.  Mechanisms of pain in peripheral neuropathy , 1999, Acta neurologica Scandinavica. Supplementum.

[39]  M. Devor,et al.  Membrane Potential Oscillations in Dorsal Root Ganglion Neurons: Role in Normal Electrogenesis and Neuropathic Pain , 1999, The Journal of Neuroscience.

[40]  P. Franklin Pain, pain, go away... , 1997, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[41]  J. Levine,et al.  Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. , 1996, Progress in brain research.

[42]  P. Benfield,et al.  Venlafaxine. A review of its pharmacology and therapeutic potential in depression. , 1995, Drugs.

[43]  G. Bennett The role of the sympathetic nervous system in painful peripheral neuropathy , 1991, PAIN.

[44]  M. Zimmermann,et al.  The bradykinin-induced release of substance P from nerve fibre endings in the rat saphenous nerve neuroma is not related to electrophysiological excitation , 1988, Neuroscience Letters.

[45]  R. Hughes,et al.  Peripheral neuropathy. , 1982, The New England journal of medicine.